Input. Theravance shall regularly advise Clinigen of the status of all Joint Invention Patents and, at Clinigen’s request, shall provide Clinigen with copies of all ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. documentation concerning Joint Invention Patents, including all correspondence to and from any Governmental Authority. Prior to filing patent applications relating to Joint Inventions or significant prosecution documents relating to Joint Invention Patents, Theravance shall solicit Clinigen’s advice on the content of the patent application or prosecution document and Theravance shall take into account Clinigen’s reasonable comments related thereto, unless (without fault of Theravance) deadlines will not permit such review or Clinigen notifies Theravance that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, Theravance shall have the final decision-making authority with respect to any action relating to Joint Inventions or Joint Invention Patents subject to the provisions of Section 13.02(f) and Section 13.02(i). Theravance and Clinigen shall agree on which Countries in the Territory corresponding Joint Invention Patents shall be filed within the priority period. For all Countries outside the Territory, Theravance shall make the final decision regarding which Countries corresponding Joint Invention Patents shall be filed subject to the provisions of Section 13.02(f).
Appears in 4 contracts
Samples: Commercialization Agreement, Commercialization Agreement (Theravance Biopharma, Inc.), Commercialization Agreement (Theravance Biopharma, Inc.)
Input. Theravance shall regularly advise Clinigen of the status of all Joint Invention Theravance Patents in the Territory, and, at Clinigen’s request, shall provide Clinigen with copies of all ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. documentation concerning Joint Invention PatentsTheravance Patents in the Territory, including all correspondence to and from any Governmental Authority. Prior to filing patent applications relating to Joint Theravance Inventions or significant prosecution documents relating to Joint Invention PatentsTheravance Patents in the Territory, Theravance shall solicit Clinigen’s advice on the content of the patent application or prosecution document and Theravance shall take into account Clinigen’s reasonable comments related thereto, unless (without fault of Theravance) deadlines will not permit such review or Clinigen notifies Theravance that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, Theravance shall have the final decision-making authority with respect to any action relating to Joint Theravance Inventions or Joint Invention Theravance Patents subject to the provisions of Section 13.02(f13.02(d) and Section 13.02(i). Theravance and Clinigen shall agree on which Countries in the Territory corresponding Joint Invention Theravance Patents shall be filed within the priority period. For all Countries outside the Territory, Theravance shall make the final decision regarding which Countries corresponding Joint Invention Theravance Patents shall be filed subject to the provisions of Section 13.02(f)filed.
Appears in 4 contracts
Samples: Commercialization Agreement, Commercialization Agreement (Theravance Biopharma, Inc.), Commercialization Agreement (Theravance Biopharma, Inc.)
Input. Theravance Clinigen shall regularly advise Clinigen Theravance of the status of all Joint Invention Clinigen Patents and, at ClinigenTheravance’s request, shall provide Clinigen Theravance with copies of all ***CERTAIN INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. documentation concerning Joint Invention Clinigen Patents, including all correspondence to and from any Governmental Authority. Prior to filing patent applications relating to Joint Clinigen Inventions or significant prosecution documents relating to Joint Invention PatentsClinigen Patents outside the Territory, Theravance Clinigen shall solicit ClinigenTheravance’s advice on the content of the patent application or prosecution document and Theravance Clinigen shall take into account ClinigenTheravance’s reasonable comments related thereto, unless (without fault of TheravanceClinigen) deadlines will not permit such review or Theravance notifies Clinigen notifies Theravance that it does not wish to review such documents. In the event of a dispute between the Parties regarding the content of patent applications or prosecution documents, Theravance Clinigen shall have the final decision-making authority with respect to any action relating to Joint Clinigen Inventions or Joint Invention Clinigen Patents subject to the provisions of Section 13.02(f13.02(e) and Section 13.02(i). Theravance and Clinigen shall agree on which Countries in the Territory corresponding Joint Invention Clinigen Patents shall be filed within the priority period. For all Countries outside the Territory, Theravance Clinigen shall make the final decision regarding which Countries corresponding Joint Invention Clinigen Patents shall be filed filed, subject to the provisions of Theravance’s Step-In-Rights in Section 13.02(f13.02(e).
Appears in 3 contracts
Samples: Commercialization Agreement (Theravance Biopharma, Inc.), Commercialization Agreement (Theravance Biopharma, Inc.), Commercialization Agreement (Theravance Inc)
